Myriad Genetics And Personalis Partner To Market Solutions To Pharma Customers
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics has partnered with Personalis to market their combined solutions to pharmaceutical customers. The collaboration aims to enhance Myriad's hereditary cancer tests with Personalis' advanced sequencing capabilities, potentially improving patient outcomes and accelerating drug development processes.
November 16, 2023 | 9:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Myriad Genetics' partnership with Personalis could lead to increased demand for its hereditary cancer tests, potentially boosting revenue and market share.
The partnership with Personalis is likely to be viewed positively by investors as it could expand Myriad Genetics' market reach and enhance its product offerings. This strategic move may lead to increased sales and a stronger competitive position in the genetic testing market.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80